anti-EGFR/anti-B7-H3 CAR T cells

{
  "id": "MLC-T-ONC-010599",
  "term": "anti-EGFR/anti-B7-H3 CAR T cells",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the epidermal growth factor receptor (EGFR) and the immunoregulatory protein B7-homologue 3 (B7-H3, CD276), with potential immunostimulating and antineoplastic activities. Upon administration, the anti-EGFR/anti-B7-H3 CAR T cells target and bind to EGFR-expressing tumor cells and B7-H3-expressing immune and tumor cells, thereby inducing selective toxicity in these cells. EGFR, overexpressed by a variety of cancer cell types, plays a key role in tumor cell proliferation, tumor angiogenesis and radio- and chemoresistance. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells. It is a negative regulator of T-cell activation and its overexpression plays a key role in tumor cell invasion and metastasis.",
  "synonyms": [
    "EGFR/B7-H3-targeted CAR T cells",
    "anti-EGFR/anti-B7H3 CAR T cells",
    "anti-EGFR/anti-CD276 CAR T cells"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-egfr-anti-b7-h3-car-t-cells/"
}